A Clinical Trial of Tri-Iodothyronine as a Hormone Potentiator in Advanced Breast Cancer

Stoll, Basil A.

doi:10.1038/bjc.1962.48

Cited by 5 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thyroid hormone medication has also been claimed to be beneficial for the treatment of advanced breast cancer (Loeser, 1954;Lemon, 1957;Gardner et al, 1962;Witt et al, 1963). Loeser (1954) stated that thyroid hormone "given in massive dosage in cases of inoperable cancer of breast and genitals, slowed down cancerous growth", but others (Stoll, 1962;Emery and Trotter, 1963;Lyons, 1968; O'Bryan et al, 1974) found thyroid hormone of no curative or palliative value in breast cancer patients. Rather, thyroid hormone excess has been observed to be associated with decreased survival rates from breast cancer (Moossa et al, 1973).…”

Section: Thyroid Hormone Treatment Of Breast Cancermentioning

confidence: 99%

Thyroid disease in relation to breast cancer

Vorherr

1978

Klin Wochenschr

View full text Add to dashboard Cite

A controversy exists in regard to thyroid function and breast cancer. Hypothyroidism has been suggested as being either protective from breast cancer or predisposing to the disease. It has been hypothesized that a deficiency in circulating thyroid hormones may hypersensitize the mammary glandular epithelium toward prolactin and estrogens, thus aiding the development of breast neoplasia. On the other hand, thyroid hormone replacement therapy has been connected with an increased risk of breast cancer, but this has been contested. At this time the American Thyroid Association recommends that, if indicated, hypothyroid patients should take their thyroid hormone medication. Hyperthyroidism has been associated with a decreased risk of breast cancer. Also, in hyperthyroid patients with inoperable breast cancer, the malignant growth is thought to be slowed. However, this, too has been disputed. Moreover, hyperthyroidism has been connected with the development of breast cancer in premenopausal women. At present no role of thyroid hormone in the pathobiology of breast cancer can be defined. It seems that the "thyroid-breast cancer controversy" can only be resolved by a prospective study preferably on postmenopausal women correlating thyroid (T3, T4, PBI), pituitary (TSH, TRH, Prolactin), and adrenocortical (androgens) function tests with the clinical examination of thyroid, breast, and genital apparatus and determination of the estrogen status (vaginal smear, plasma estrogens) as well.

show abstract

Section: Thyroid Hormone Treatment Of Breast Cancermentioning

confidence: 99%

Thyroid disease in relation to breast cancer

Vorherr

1978

Klin Wochenschr

View full text Add to dashboard Cite

show abstract

“…Emery & Trotter (1963) have recently reported on a double-blind trial which showed conclusively that triiodothyronine in doses up to 120 pg daily did not influence the course of the disease, but in this study the thyroid hormone was given by itself for the duration of the investigation. Stoll (1962) has described the failure of thyroid extract and triiodothyronine to affect the response to treatment when combined with synthetic cestrogens. Gardner et al (1962) on the other hand claimed a remission rate of 24 % in 46 postmenopausal patients treated with prednisone and triiodothyronine.…”

Section: Factors Affecting Steroid Metabolismmentioning

confidence: 99%

Hormonal Control of Cancer

1963

Proceedings of the Royal Society of Medicine

View full text Add to dashboard Cite

Neoplastic disease and thyrotoxicosis

Wanebo¹,

Benua²,

Rawson³

1966

Cancer

View full text Add to dashboard Cite

The relationship of thyrotoxicosis and malignancy has been studied in a cancer center. There was a lower incidence of cancer in patients with hyperthyroidism (25%) than in admissions generally (59.8%) but this probably represents a sampling difference. Of 300 women with thyrotoxicosis, 83 had neoplastic disease. Of the women with hyperthyroidism and cancer (excluding thyroid and skin malignancies), 56% had breast primaries. This is significantly different from the 36% incidence of breast cancer among all women with malignant neoplasms at the center. The incidence of hyperthyroidism was only 0.25% in females with breast cancer but the diagnosis of both diseases was made in 21 of 40 women within the same year. Such a time‐linked occurrence is statistically significant. No effect on survival was demonstrated. The significance of these findings is discussed.

show abstract

A Clinical Trial of Tri-Iodothyronine as a Hormone Potentiator in Advanced Breast Cancer

Cited by 5 publications

References 6 publications

Thyroid disease in relation to breast cancer

Thyroid disease in relation to breast cancer

Hormonal Control of Cancer

Neoplastic disease and thyrotoxicosis

Contact Info

Product

Resources

About